295 related articles for article (PubMed ID: 32564243)
1. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Horibe K; Morris JD; Tuglus CA; Dos Santos C; Kalabus J; Anderson A; Goto H; Ogawa C
Int J Hematol; 2020 Aug; 112(2):223-233. PubMed ID: 32564243
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
[TBL] [Abstract][Full Text] [Related]
3. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Kobayashi Y; Oh I; Miyamoto T; Lee WS; Iida H; Minami H; Maeda Y; Jang JH; Yoon SS; Yeh SP; Tran Q; Morris J; Franklin J; Kiyoi H
Asia Pac J Clin Oncol; 2022 Jun; 18(3):311-318. PubMed ID: 34185953
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
6. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
7. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
8. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E; Zugmaier G; Agrawal V; Martínez-Sánchez P; Rifón Roca JJ; Cassaday RD; Böll B; Rijneveld A; Abdul-Hay M; Huguet F; Cluzeau T; Díaz MT; Vucinic V; González-Campos J; Rambaldi A; Schwartz S; Berthon C; Hernández-Rivas JM; Gordon PR; Brüggemann M; Hamidi A; Chen Y; Wong HL; Panwar B; Katlinskaya Y; Markovic A; Kantarjian H
Am J Hematol; 2024 Apr; 99(4):586-595. PubMed ID: 38317420
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort.
Goto H; Ogawa C; Iida H; Horibe K; Oh I; Takada S; Maeda Y; Minami H; Nakashima Y; Morris JD; Kormany W; Chen Y; Miyamoto T
Acta Haematol; 2022; 145(6):592-602. PubMed ID: 35790143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
11. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
12. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC; Gökbuget N
Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
[TBL] [Abstract][Full Text] [Related]
17. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]